These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34295843)

  • 1. The Cancer-Immunity Cycle in Multiple Myeloma.
    Casey M; Nakamura K
    Immunotargets Ther; 2021; 10():247-260. PubMed ID: 34295843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
    Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
    Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T Therapy in Relapsed Refractory Multiple Myeloma.
    Ding H; Wu Y
    Curr Med Chem; 2024; 31(27):4362-4382. PubMed ID: 37779413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.
    Bhatt P; Kloock C; Comenzo R
    Curr Oncol; 2023 Feb; 30(2):2322-2347. PubMed ID: 36826140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.
    Dima D; Ullah F; Mazzoni S; Williams L; Faiman B; Kurkowski A; Chaulagain C; Raza S; Samaras C; Valent J; Khouri J; Anwer F
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
    Kegyes D; Constantinescu C; Vrancken L; Rasche L; Gregoire C; Tigu B; Gulei D; Dima D; Tanase A; Einsele H; Ciurea S; Tomuleasa C; Caers J
    J Hematol Oncol; 2022 Jun; 15(1):78. PubMed ID: 35672793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
    Castella M; Fernández de Larrea C; Martín-Antonio B
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of NK cells in multiple Myeloma therapy.
    Khan AM; Devarakonda S; Bumma N; Chaudhry M; Benson DM
    Expert Rev Hematol; 2019 Jun; 12(6):425-435. PubMed ID: 31070067
    [No Abstract]   [Full Text] [Related]  

  • 11. BCMA in Multiple Myeloma-A Promising Key to Therapy.
    Kleber M; Ntanasis-Stathopoulos I; Terpos E
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies.
    Stalker ME; Mark TM
    Curr Oncol; 2022 Jun; 29(7):4464-4477. PubMed ID: 35877215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma.
    Janakiram M; Arora N; Bachanova V; Miller JS
    Transplant Cell Ther; 2022 Feb; 28(2):61-69. PubMed ID: 34634499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimization of treatment strategy for relapsed or refractory multiple myeloma].
    Ito S
    Rinsho Ketsueki; 2023; 64(9):1074-1082. PubMed ID: 37899185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
    Díez-Alonso L; Falgas A; Arroyo-Ródenas J; Romencín PA; Martínez A; Gómez-Rosel M; Blanco B; Jiménez-Reinoso A; Mayado A; Pérez-Pons A; Aguilar-Sopeña Ó; Ramírez-Fernández Á; Segura-Tudela A; Perez-Amill L; Tapia-Galisteo A; Domínguez-Alonso C; Rubio-Pérez L; Jara M; Solé F; Hangiu O; Almagro L; Albitre Á; Penela P; Sanz L; Anguita E; Valeri A; García-Ortiz A; Río P; Juan M; Martínez-López J; Roda-Navarro P; Martín-Antonio B; Orfao A; Menéndez P; Bueno C; Álvarez-Vallina L
    Sci Transl Med; 2024 Feb; 16(734):eadg7962. PubMed ID: 38354229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
    Sanchez L; Dardac A; Madduri D; Richard S; Richter J
    Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.